Close

Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...) Aug 6, 2018 09:27AM
Unusual 11 Mid-Day Movers 4/1: (SKYS) (CSII) (AKTX) Higher; (ROVI) (UPL) (AKER) Lower Apr 1, 2016 01:00PM
Pre-Open Stock Movers 04/01: (CSII) (VJET) (TSLA) Higher; (BBRY) (SUNE) (GNCA) Lower (more...) Apr 1, 2016 09:25AM
Notable Analyst Rating Changes 1/25: (RSYS) (HD) (JBHT) Upgraded; (REGN) (TWTR) (WFM) Downgraded Jan 25, 2016 10:30AM
Notable Analyst Rating Changes 2/20: (MRVL) (DSW) (KN) Upgraded; (FUEL) (HLSS) (REGN) Downgraded Feb 20, 2015 10:46AM


Apr 16, 2014 10:38AM Notable Analyst Rating Changes 04/16: (SFUN) (TWTR) (YELP) Upgraded; (INTC) (UNH) (GDP) Downgraded
Jul 25, 2012 12:11PM Streetinsider.com's Hot Lunchtime Reads 07/25: (NFLX) (AAPL) (ALTR) (REGN) (AMRN) (INFN)
Aug 17, 2011 11:14AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Priority, Shmyriority - 90 More Days to Prepare for Launch - Remain Positively Inclined
Aug 1, 2011 08:12AM Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Upcoming August Event May Signal August Opportunities
Jun 20, 2011 07:33AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Summer Solstice & Extra Daylight for AMD Patients with a New Potential Treatment Option
May 9, 2011 07:26AM Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Raising PT
Apr 27, 2011 09:28AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); VELOUR...Looking Good! Positive Phase 3 Results in CRC Add Another Major Disease Category
Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
Mar 11, 2011 08:19AM Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Failed Aflibercept Trial in 2nd-line Lung Cancer Doesn’t Change Our Thesis
Feb 17, 2011 04:28PM Needham & Company maintains a 'Buy' on Regeneron Pharma (REGN); Believe 2011 Will Build on Successes of 2010
Feb 14, 2011 07:59AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Angiogenesis Mtg Highlights Robust Full Dataset for Multiple VEGF Trap-Eye Trials
Jan 5, 2011 08:23AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Positioned for Transformational Year
Nov 12, 2010 08:12AM Needham & Company Reiterates a 'Buy' Rating on Regeneron Pharma (REGN)
Aug 2, 2010 09:16AM Needham & Company Reiterates a 'Buy' Rating on Regeneron Pharmaceuticals (REGN); Multiple Catalysts in 2H10 to Potentially Drive the Stock Valuation
Jul 16, 2010 08:49AM Needham & Company Reiterates a 'Buy' on Regeneron Pharmaceuticals (REGN); Investor Day Review – Have More Confidence in the Clinical Trial and Commercialization in Gout
May 3, 2010 07:45AM Needham & Company Reiterates a 'Buy' on Regeneron Pharmaceuticals (REGN); Preview Shows Progress in Both Late-Stage Programs
Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)